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Abstract 
Objective: Motor neuron disease (MND) is a rapidly progressive 
neurodegenerative condition with no known cure. MND can affect every aspect 
of a person’s life and has been associated with a wide range of psychological 
difficulties, which can occur from pre-diagnosis through to the condition’s later 
stages. However, very little research has been conducted on psychological 
interventions for people with MND (pwMND). This paper aimed to provide the 
first review specifically targeting psychological interventions in MND, and offer 
potential directions for future research.   
Methods: A scoping review was carried out across five major databases 
(PubMed, PsycINFO, CINAHL, Academic Search Ultimate, and Cochrane 
Library) until 1st of March 2020.  
Results: From an initial return of 1278 citations, ten papers were included in the 
review. These included three randomised controlled trials (RCTs), two quasi-
experiments, three uncontrolled pretest-posttest designs, one single case study, 
and one qualitative secondary analysis. The existing studies focused on a limited 
number of psychological outcomes and did not take into account site of MND 
onset or level of depression/anxiety before intervention. Implications for clinical 
practice are discussed and suggestions for future research are provided.  
Conclusions: The literature on psychological interventions is still extremely 
sparse. Mindfulness-based stress reduction (MBSR) and cognitive behavioural 
therapy (CBT) based on the stress-coping model show promise in RCTs but 
require further evaluation. The need for further development and evaluation of 
psychological interventions to improve the well-being of pwMND cannot be 
overstated, particularly as the struggle toward the discovery of an effective 
treatment for MND continues. 
Keywords: motor neuron disease; amyotrophic lateral sclerosis; psychotherapy; 
clinical psychology; psychological interventions.  
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Introduction 
Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a 
life-limiting neurodegenerative condition characterised by the progressive death of both 
upper and lower motor neurons (1). It affects about 2 in 100,000 people worldwide (2,3) 
and leads to weakening and wasting of muscles (up to complete paralysis), dysarthria, 
dysphagia, and severe respiratory impairment. The age of onset is typically between 50 
and 70 (4), and the subsequent average life expectancy is three to five years. For most 
people with MND (pwMND), the disease begins with weakening in one of the limbs 
(‘limb onset’; (5)), while about 30% of individuals show early swallowing and speech 
impairments (‘bulbar onset’; (1)). As no cure is currently available (5,6), the clinical 
management relies mainly on symptomatic and palliative care, with the aim of 
maintaining or improving quality of life (7).  
Psychological difficulties in pwMND 
Since no specific test for MND is currently available, the diagnosis typically consists of 
multiple medical examinations aimed at excluding any mimicking conditions, which 
frequently translate into a long and uncertain path to diagnosis, lasting on average 10-18 
months (4). This may, in turn, lead pwMND to experience high levels of anxiety and 
depression (8,9) and to develop coping strategies based on denial and avoidance (10–
12), which can lead to poorer quality of life (13,14).  
Even before diagnosis, the physical symptoms of MND and the way they are 
perceived socially can affect a person’s independence, their roles and identity, 
confidence, and self-esteem. People with bulbar onset generally show higher levels of 
psychological distress (13,15), and research indicates that breathing, swallowing, and 
speech difficulties are associated with this distress (16). For example, dysarthria can 
impact psychosocial factors (17,18), leading to changes to perceived identity, feelings 
of self-consciousness, and negative emotions (19,20). Dysphagia has been linked to fear 
of choking (21–24), loss of pleasure deriving from eating (25–27), and loss of control 
(10,28–30). However, with the exception of fear of choking, many of these 
psychosocial and emotional consequences of physical symptoms would also apply to 
people with limb onset. In addition, regardless of onset type, symptoms are progressive, 
and many people eventually develop a combination of limb and bulbar symptoms (1). 
Therefore, the losses are cumulative and significant adjustment must continue 
throughout the course of the disease (7). 
Moreover, around 40 to 50% of pwMND are estimated to experience some form 
of cognitive impairment – mainly involving executive functioning, language and verbal 
fluency (31,32) – and about 10-15% meet the full criteria for a diagnosis of 
frontotemporal dementia (33,34). As cognitive flexibility and flexible affective 
processing both represent predictors of trait resilience (35), cognitive impairments are 
likely to affect the emotional coping abilities of pwMND, as well as their response to 
psychological treatment.  
In spite of the fact that recent qualitative evidence emphasised the need for 
tailored psychological approaches for pwMND (37,39), very little research has been 
conducted so far on the topic (36–38). One existing review that focused on both 
pharmacological treatments and psychological interventions concluded that evidence for 
the latter up to 2015 was too limited to provide any sensible clinical recommendations 
(38). However, very broad search terms were used for psychological interventions (e.g., 
‘psychological therapy’ or ‘counselling’), with none targeting specific types of therapy. 
Similarly, another review on multiple neurodegenerative conditions up to 2016  pointed 
out the lack of studies on psychological interventions in MND, but, due to its 
predominant focus on cognitive rehabilitation, it only included studies involving 
pwMND with cognitive impairment (40). 
Thus, the aim of the present review was to focus  specifically on psychological 
interventions in pwMND by adopting a more detailed and targeted search strategy and 
including different therapy models. In addition, it aimed to include any papers published 
since the mid 2010s.  
Materials and methods 
Methodological approach 
A scoping review was carried out, based on the guidelines by the Joanna Briggs 
Institute (41). This approach was adopted since it specifies a replicable database search 
without the need for a narrower question, which would have been incompatible with the 
current paucity of literature (36–38,42,43).  
Inclusion criteria 
To be included, studies had to a) be related to pwMND; b) involve individuals aged 18 
or above; c) describe the delivery of any form of psychological intervention with 
pwMND. Interventions targeting caregivers as well were included as long as the data 
for pwMND could be extracted. Qualitative designs were considered eligible if they 
related to a form of intervention. Studies not adhering to the inclusion criteria, reviews, 
commentaries, protocols, editorials, and letters were excluded.  
Quality assessment 
Since a formal quality appraisal is not typically performed in scoping reviews (41,44), 
this was not included in the present review. However, efforts were made to point out 
methodological and clinical limitations whenever present.   
Procedure 
A combination of free text terms was adopted to search Academic Search Ultimate, 
CINAHL, Cochrane Library, PsycINFO, and PubMed up until 1st March 2020. 
Reference lists of included studies were hand-searched. Table 1 shows the logic grid for 
the search strategy, while Table 2 illustrates the adopted search terms. 
Initially, one reviewer (NZ) screened all titles and abstracts against the inclusion 
criteria. The full-text of the remaining citations were then screened by another reviewer 
(FE) and confirmed by a third reviewer (JS). Figure 1 illustrates the PRISMA flow 
diagram of the study selection. The final data extraction was performed independently 
by two reviewers (NZ, FE), and double-checked for accuracy by further two reviewers 
(EM, NOS).  
Results 
The initial search across the databases returned a total of 1278 studies, which were 
narrowed down to 764 after filtering and deduplication. Titles and abstracts were then 
screened thoroughly, and a total of 14 articles remained for full-text screening. 
Eventually, 10 studies were included. These were three randomised controlled trials 
(RCTs), two quasi-experiments, three uncontrolled pretest-posttest designs, one single 
case study, and one qualitative secondary analysis. Table 3 summarises the key 
characteristics and results of the eligible studies, while Table 4 lists the excluded full-
texts along with the rationale for exclusion. 
Randomised controlled trials  
Averill and colleagues (45) carried out an RCT to compare the effect of expressive 
disclosure on psychological well-being of pwMND compared to no psychological 
treatment. Although measures of affect, depression, and quality of life were adopted, an 
ad-hoc composite well-being measure consisting of the mean of the standardised scores 
was used for the main analysis. The results showed that the intervention group had 
significantly higher levels of well-being compared to controls at three months (i.e., post-
intervention). Interestingly, ambivalence over emotional expression was found to 
mediate the effect of intervention on well-being, with participants in both groups who 
had higher ambivalence over emotional expression having lower well-being. However, 
participants with higher ambivalence over emotional expression who participated in the 
intervention had improved well-being at three months, whereas those in the control 
group had decreased well-being. The benefits of expressive disclosure were not 
maintained at six months. 
Pagnini et al. (46) evaluated an 8-week MND-specific meditation programme 
based on mindfulness-based stress reduction (MBSR; (47)) in comparison with 
treatment as usual. The results showed significant improvements for levels of anxiety, 
depression, and quality of life immediately post-intervention, as well as at 6- and 12-
months follow-up. In addition, a secondary qualitative analysis of the same study (48) 
was carried out adopting grounded theory and reported that the participants believed the 
intervention had a positive impact on their psychological well-being, promoted by an 
increase in acceptance and a non-judgmental attitude.  
Van Groenestijn et al. (49) designed a CBT intervention based on the stress-
coping model consisting of six modules specifically tailored to pwMND and their 
caregivers. However, the RCT had to stop prematurely due to difficulties with 
recruitment. The analysis of the preliminary data showed significantly less deterioration 
in mental quality of life in the intervention group when compared to controls receiving 
treatment as usual.  
Other designs 
Díaz et al. (50) delivered a 4-session CBT programme combined with counselling 
techniques, and compared it to treatment as usual in a quasi-experiment. Assessments 
were only carried out at baseline and post-intervention. In the intervention group the 
results showed a significant decrease in the proportion of participants with moderate 
and severe anxiety (from 63.3% to 16.7%) and those with moderate and severe 
depression (from 36.7% to 10.0%). No significant changes were observed in the control 
group.  
Palmieri et al. (51) adopted an uncontrolled pretest-posttest design with pwMND 
to pilot a psychodynamic hypnosis 4-week intervention combined with domiciliary 
visits and self-hypnosis training. At post-intervention, the results showed a significant 
decrease in anxiety and depression, as well as lower negative affect and higher 
spirituality components of quality of life. The same intervention was later evaluated 
with a quasi-experimental design (52) which enrolled one-by-one matched controls with 
MND. The findings were consistent with the pilot, showing improvements in 
psychological outcomes immediately after the treatment, improvements in anxiety 
maintained at 3- and 6-month follow-up.   
Aoun et al. and Bentley et al. (53,54) reported on the same uncontrolled pretest-
posttest feasibility study conducted to evaluate dignity therapy (DT) with pwMND and 
their caregivers. The results at post-intervention showed that, while DT was well 
received by the participants – including those who required augmentative and 
alternative communication (ACC) – no significant differences were observed in quality 
of life for either pwMND or their caregivers.  
Finally, García Pérez and Dapueto (55) reported a single case of computer-
assisted psychotherapy (using ACC) with a 66-year-old woman with MND. The 
intervention was based on cognitive-behavioural and expressive-supportive models and 
techniques, and reportedly led to decrease in psychological distress and increased 
symptom control, communication, autonomy, dignity, and self-esteem. ACC was 
reported to work well in combination with the computer-assisted intervention. However, 
no quantitative data were provided to evidence these findings.  
Discussion 
To our knowledge, the present review was the first to target studies on 
psychological interventions with pwMND. While the detailed search strategy and five-
year interval since the only two more general reviews available (38,40) generated five 
additional citations, doubling the total, this has still only brought the number of studies 
to ten. In addition, only three (45,46,49) were randomised control trials (RCTs), while 
the remaining were mainly quasi-experimental and uncontrolled designs. The current 
literature also neglects important aspects of psychological distress. Therefore, more 
research into psychological approaches to improve the emotional well-being and quality 
of life for pwMND is urgently required. In particular, as the current evidence base 
mainly consists of small n and low powered investigations, further research should 
focus on building on these by enrolling larger and sufficiently powered samples 
(possibly across multiple locations) as well as adopting more empirically robust 
methods such as RCTs.  
Nevertheless, it is encouraging to see that all of the studies report either 
maintenance or improvements in psychological outcome variables (where these are 
measured), and that participants found the interventions acceptable. Therefore, the 
initial indications are that psychological interventions are unlikely to be harmful and 
have the potential to be helpful. However, the very limited number of studies means that 
the evidence is insufficient to make clear recommendations about which specific 
therapy models are most effective for specific problems. In fact, the literature to date 
suggests that multiple therapy models could be useful, either targeting similar or distinct 
aspects of psychological distress/well-being (46,49,52).  
The discussion section will attempt to focus on four major psychological 
challenges frequently associated with MND, namely anxiety and depression, emotional 
difficulties, and quality of life. However, given the very limited evidence available, 
these results should be interpreted cautiously. 
Anxiety and depression 
Anxiety and depression represent two of the most common psychological difficulties in 
pwMND, with estimates reaching up to 44% and 30% of affected individuals 
respectively (56), but have been the subject of only one RCT (46).  This study, using a 
tailored form of MBSR, has shown positive and long-lasting beneficial reductions in 
levels of anxiety and depression. One further RCT (45) reported positive results for the 
adoption of expressive disclosure by using a psychological well-being composite score.  
However, the specific effect on depression was unclear.  
Preliminary evidence from quasi-experimental and uncontrolled designs also 
suggests promising results for CBT with counselling techniques (50) and 
psychodynamic hypnosis (51,52) on anxiety and depression. Anecdotal benefits have 
also been reported for computer-assisted CBT with expressive-supportive techniques in 
the treatment of anxiety specifically.  
Emotional difficulties 
Difficulties with emotions are commonly observed in pwMND (57), and may include 
deficits in emotion perception and emotion regulation, including emotional lability 
(10,58–61). These kinds of difficulties are thought to be due to a combination of 
psychological adjustment to the condition (10,62) and potential underlying frontal 
cognitive deterioration (58). However, to date no psychological intervention study has 
specifically targeted difficulties with these aspects of emotion in pwMND. The only 
preliminary evidence currently available comes from an RCT adopting expressive 
disclosure and suggesting that ambivalence over emotional expression may mediate the 
effect of the intervention on well-being (45). It is unclear whether these results focused 
on ambivalence would translate to people experiencing difficulties with emotion 
perception or emotion regulation. 
Quality of life 
Due to MND’s rapid progression and the lack of treatment options (1), the maintenance 
or improvement of quality of life currently represents the mainstay of clinical 
management (7). The importance of psychological interventions is underpinned by 
evidence suggesting that psychological difficulties are stronger predictors of poor 
quality of life than the physical impairments caused by the disease (63–66).  
To date only two RCTs (46,49) have explored interventions to address quality of 
life specifically, showing benefits for MND-tailored MBSR (corroborated by a 
secondary qualitative analysis (48)) and possibly CBT. A third RCT (45) found a 
positive short-term (i.e., three months) effect of expressive disclosure on a 
psychological well-being composite score. However, the impact of this intervention 
specifically on quality of life remains unclear.   
Less rigorous findings available from quasi-experimental and uncontrolled 
designs showed promising preliminary evidence for treatments based on 
psychodynamic hypnosis combined with domiciliary visits and self-hypnosis training 
sessions (51,52), while no changes were observed when adopting DT (53,54).  
Clinical implications and future directions 
The results of the present review show that our understanding of whether psychological 
interventions are effective for pwMND is still extremely limited. According to the data 
available to date, MND-tailored MBSR (46,48) has the strongest evidence base for 
improving anxiety, depression, and quality of life. While this represents a promising 
start, it is still far too early to be certain that this is the best possible psychological 
intervention. In addition, more research is required to assess the efficacy of other 
approaches, including psychodynamic hypnosis (51,52) and CBT based on the stress-
coping model (47) or combined with counselling techniques (50).  
Interestingly, all but one of the approaches that have shown promise in MND to 
date include elements of CBT, either directly or in the principles underpinning them. 
MBSR is one of a number of ‘third wave’ interventions that grew from CBT and 
include a focus on mindfulness. Acceptance and commitment therapy (ACT) is another 
approach that has not yet been evaluated in MND, but appeared promising in other 
health and palliative care settings (67,68). Therefore, further research on these 
approaches interventions would be particularly relevant, as they also have the additional 
advantage of already being widely available (69,70), which would facilitate their 
adoption in other clinical areas. It is also possible that existing manualised forms of 
face-to-face and internet-based CBT could be adapted specifically for people with MND 
(69).  
A number of limitations were evident in all the studies included in this review. 
Firstly, as mentioned above, some of the results were characterised by low levels of 
methodological robustness –  such as non-randomised (50,52) uncontrolled (51,53,54), or 
single case (55) designs –  or inadequate  reports of finding (e.g., no quantitative data 
available for (55)). Secondly, despite evidence that bulbar onset MND is associated 
with higher levels of depression and anxiety (13,15,16), none of the studies 
differentiated between site of onset in reporting their results. In addition, few studies 
reported whether participants with MND showed clinically significant levels 
psychological distress prior to the interventions and – even when these were reported – 
the increased variability due to the adoption of assessment tools based on different 
methodologies (e.g., semi-structured interviews v.  self-report questionnaires; (71)) 
should be taken into account when pooling the results. Considering that clinical services 
would generally only receive referrals for people experiencing levels of psychological 
difficulties high enough to be classified as ‘clinical’ on standardised measures, it is 
important to understand the effectiveness of these interventions on people experiencing 
clinically significant depression or anxiety, as well as potentially understanding its 
effect in people not reaching these thresholds. Interventions building resilience as 
opposed to targeting specific symptoms might also be useful given the varied and 
fluctuating nature of the psychological challenges (72). 
The current literature, although limited, suggests that psychological 
interventions could augment usual clinical care, which includes important support and 
information already offered by non-psychology healthcare professionals and third sector 
volunteers. Therefore, future MND research focused on further development and 
evaluation of psychological interventions is strongly warranted. In particular, when 
developing interventions, attention should be paid to the psychosocial, emotional, and 
physical changes that can occur in pwMND to ensure that the approach is relevant and 
acceptable. When evaluating interventions, attention should be paid to participants’ 
levels of distress at the beginning of therapy, site of MND onset, emotional perception 
and regulation difficulties (10,58–61), psychosocial issues (65,73,74), cognitive and 
behavioural change (75), and loss of perceived control (10,28–30). It would also be 
helpful for studies to identify the proposed mechanisms of change that affect outcomes 
(e.g., alliance, behaviour change, present moment focus) and include consideration of 
which psychological outcomes are being targeted (e.g., anxiety, depression, quality of 
life, or other). Building on this, the direct comparison of the effectiveness of different 
types of therapies would be desirable, again keeping in mind how clinical and baseline 
psychological variables could interact with treatment approach. 
Ultimately, as the struggle toward the discovery of an effective treatment for 
MND continues, the need for psychological interventions to increase the psychological 
well-being and quality of life of people with MND cannot be overstated. 
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Table 1. Logic grid for search strategy. 





Acceptance and commitment therapy  
Behavio* therapy  
Cognitive analytic therapy 
Cognitive behavio* therapy  
Cognitive therapy 
Compassion* focused therapy 
Counsel* 
Couple* therapy 
Dialectical behavioral therapy 
Emotion focused therapy 
Emotive behavio* therapy 










Mindfulness-based cognitive therapy 



















Table 2. Overview of adopted search terms and identified items per database. 
Search terms 
(Motor neuron* disease AND Acceptance and commitment therapy) OR (Motor neuron* disease AND Behavio* therapy) OR (Motor neuron* disease AND Cognitive 
analytic therapy) OR (Motor neuron* disease AND Cognitive behavio* therapy) OR (Motor neuron* disease AND Cognitive therapy) OR (Motor neuron* disease AND 
Compassion* focused therapy) OR (Motor neuron* disease AND Counsel*) OR (Motor neuron* disease AND Couple* therapy) OR (Motor neuron* disease AND 
Dialectical behavioral therapy) OR (Motor neuron* disease AND Emotion focused therapy) OR (Motor neuron* disease AND Emotive behavio* therapy) OR (Motor 
neuron* disease AND Eye movement desensiti* and reprocessing) OR (Motor neuron* disease AND Family therapy) OR (Motor neuron* disease AND Gestalt therapy) OR 
(Motor neuron* disease AND Group* therapy) OR (Motor neuron* disease AND Integrative therapy) OR (Motor neuron* disease AND Interpersonal therapy) OR (Motor 
neuron* disease AND Meditat*) OR (Motor neuron* disease AND Metacognitive therapy) OR (Motor neuron* disease AND Mindfulness) OR (Motor neuron* disease 
AND Mindfulness-based cognitive therapy) OR (Motor neuron* disease AND Mindfulness-based stress reduction) OR (Motor neuron* disease AND Motivational 
interviewing) OR (Motor neuron* disease AND Narrative therapy) OR (Motor neuron* disease AND Person cent* therapy) OR (Motor neuron* disease AND Psychoanal*) 
OR (Motor neuron* disease AND Psychodynamic therapy) OR (Motor neuron* disease AND Psychoeducati*) OR (Motor neuron* disease AND Psychological intervention) 
OR (Motor neuron* disease AND Psychotherap*) OR (Motor neuron* disease AND Rational emotive behavio* therapy) OR (Motor neuron* disease AND Schema 
therapy) OR (Motor neuron* disease AND Self-management) OR (Motor neuron* disease AND Solution focused therapy) OR (Motor neuron* disease AND Systemic 
therapy) 
 
(Amyotrophic lateral sclerosis AND Acceptance and commitment therapy) OR (Amyotrophic lateral sclerosis AND Behavio* therapy) OR (Amyotrophic lateral sclerosis 
AND Cognitive analytic therapy) OR (Amyotrophic lateral sclerosis AND Cognitive behavio* therapy) OR (Amyotrophic lateral sclerosis AND Cognitive therapy) OR 
(Amyotrophic lateral sclerosis AND Compassion* focused therapy) OR (Amyotrophic lateral sclerosis AND Counsel*) OR (Amyotrophic lateral sclerosis AND Couple* 
therapy) OR (Amyotrophic lateral sclerosis AND Dialectical behavioral therapy) OR (Amyotrophic lateral sclerosis AND Emotion focused therapy) OR (Amyotrophic lateral 
sclerosis AND Emotive behavio* therapy) OR (Amyotrophic lateral sclerosis AND Eye movement desensiti* and reprocessing) OR (Amyotrophic lateral sclerosis AND 
Family therapy) OR (Amyotrophic lateral sclerosis AND Gestalt therapy) OR (Amyotrophic lateral sclerosis AND Group* therapy) OR (Amyotrophic lateral sclerosis AND 
Integrative therapy) OR (Amyotrophic lateral sclerosis AND Interpersonal therapy) OR (Amyotrophic lateral sclerosis AND Meditat*) OR (Amyotrophic lateral sclerosis 
AND Metacognitive therapy) OR (Amyotrophic lateral sclerosis AND Mindfulness) OR (Amyotrophic lateral sclerosis AND Mindfulness-based cognitive therapy) OR 
(Amyotrophic lateral sclerosis AND Mindfulness-based stress reduction) OR (Amyotrophic lateral sclerosis AND Motivational interviewing) OR (Amyotrophic lateral 
sclerosis AND Narrative therapy) OR (Amyotrophic lateral sclerosis AND Person cent* therapy) OR (Amyotrophic lateral sclerosis AND Psychoanal*) OR (Amyotrophic 
lateral sclerosis AND Psychodynamic therapy) OR (Amyotrophic lateral sclerosis AND Psychoeducati*) OR (Amyotrophic lateral sclerosis AND Psychological intervention) 
OR (Amyotrophic lateral sclerosis AND Psychotherap*) OR (Amyotrophic lateral sclerosis AND Rational emotive behavio* therapy) OR (Amyotrophic lateral sclerosis AND 
Schema therapy) OR (Amyotrophic lateral sclerosis AND Self-management) OR (Amyotrophic lateral sclerosis AND Solution focused therapy) OR (Amyotrophic lateral 
sclerosis AND Systemic therapy) 
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Table 3. Key characteristics of included studies. 
Citation Design  Sample Intervention  Psych. outcome Key results  
(45) RCT I: 24 
C: 24 
Expressive disclosure Emotional 
difficulties 
Significantly higher well-being in intervention 
group at 3 months, but not post intervention 
or 6 months. Mediation role of ambivalence 
over emotional expression (AEE) at 3 months. 









Significant differences between groups at 
post-intervention for depression, anxiety, 
negative emotions, QoL, and social 
interaction.  
Differences maintained at 6- and 12-months 
follow-ups.  
(48) Qualitative  
(secondary analysis of (46)) 
26 Meditation based on 
Mindfulness-based 
Stress Reduction 





Patients improvement in coping with anxiety 
and depression, in sleep problems, 
mindfulness skills, and QOL. 
Overall positive impact of intervention on 
psychological well-being, as well as increase in 
acceptance and non-judgmental attitude.  
(49) RCT (nested in larger study) I: 10 
C: 5 
CBT intervention based 
on stress-coping model 
QoL Study ended prematurely due to slow 
recruitment.  
Preliminary significant difference between 
groups on mental QoL (primary outcome).  
No differences on psychological distress 
(secondary outcome).  
 30 
(50) Quasi-experiment I: 30 
C: 24 




Significant improvements at post-intervention 
in both anxiety and depression for 
intervention group. 
No significant differences in either anxiety or 
depression for control group at post-
intervention.    






Significant improvements in depression, 
anxiety, quality of life.  
Qualitative reports of improvements in pain, 
sleep, emotional lability, fasciculation 
syndrome.  








Significant improvements in depression, 
anxiety and QoL at post-intervention for the 
intervention group.  
Improvements in anxiety maintained at 3-
month and 6-month follow-ups.  
(53) Uncontrolled pre-post 27 Dignity therapy QoL Dignity therapy well accepted by patients, 
including those who require assisted 
communication devices. Feasibility may be 
limited in small or not well-resourced services. 
No significant differences in all outcome 
measures for both groups. 
(54) Uncontrolled pre-post 29 Dignity therapy QoL Dignity therapy acceptable to people with 
MND (based on feedback questionnaires) if 
communication issues are overcome.  
 31 
No significant differences in outcome 
measures at group level. QoL not formally 
measured as outcome.  
(55) Single case 1 Computer-assisted CBT 
with expressive-
supportive techniques 
Anxiety No quantitative data provided.  
Reportedly better symptom control, improved 
communication with the team and family, 
reduction of psychological distress, and 
promotion of autonomy, dignity, and self-
esteem.  
Good acceptability of combination of 
augmentative and alternative communication 
(AAC) with psychotherapy.  
Note. C = control; I = intervention.  
  
 32 
Table 4. Articles excluded following full-text review. 
Study Design  Type of intervention  Reason for exclusion 
(76)  Uncontrolled pre-post  Mindfulness based interventions No specific results reported for pwMND 
(77) RCT Meditation based on Mindfulness-based Stress 
Reduction protocol (modified for ALS) 
Research protocol only (see (46) 
(78) Qualitative N/A Not including pwMND (interviews only 
with therapists) 
(79) RCT CBT intervention based on stress-coping model Research protocol only (see (49) 
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